Skip to main content
Journal cover image

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Publication ,  Journal Article
Filippatos, G; Farmakis, D; Metra, M; Cotter, G; Davison, BA; Felker, GM; Greenberg, BH; Hua, TA; Pang, PS; Ponikowski, P; Qian, M; Voors, AA ...
Published in: Clin Res Cardiol
June 2017

BACKGROUND: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients' outcome. We sought to assess the effects of serelaxin in patients with and without AFib. METHODS: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. RESULTS: AFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (-63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). CONCLUSIONS: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Res Cardiol

DOI

EISSN

1861-0692

Publication Date

June 2017

Volume

106

Issue

6

Start / End Page

444 / 456

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Relaxin
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
  • Female
  • Electrocardiography
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Filippatos, G., Farmakis, D., Metra, M., Cotter, G., Davison, B. A., Felker, G. M., … Teerlink, J. R. (2017). Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol, 106(6), 444–456. https://doi.org/10.1007/s00392-016-1074-x
Filippatos, Gerasimos, Dimitrios Farmakis, Marco Metra, Gad Cotter, Beth A. Davison, G Michael Felker, Barry H. Greenberg, et al. “Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.Clin Res Cardiol 106, no. 6 (June 2017): 444–56. https://doi.org/10.1007/s00392-016-1074-x.
Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, et al. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol. 2017 Jun;106(6):444–56.
Filippatos, Gerasimos, et al. “Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.Clin Res Cardiol, vol. 106, no. 6, June 2017, pp. 444–56. Pubmed, doi:10.1007/s00392-016-1074-x.
Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua TA, Pang PS, Ponikowski P, Qian M, Severin TA, Voors AA, Teerlink JR. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clin Res Cardiol. 2017 Jun;106(6):444–456.
Journal cover image

Published In

Clin Res Cardiol

DOI

EISSN

1861-0692

Publication Date

June 2017

Volume

106

Issue

6

Start / End Page

444 / 456

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Relaxin
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
  • Female
  • Electrocardiography